Status:
COMPLETED
A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
30-65 years
Phase:
PHASE3
Brief Summary
Type 2 diabetes results when the body does not produce enough insulin to regulate blood sugar. This study is designed to measure the effect of vildagliptin on the maximum insulin secretion by the panc...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes for at least 6 months
- Patients whose diabetes is controlled by diet and exercise only or patients taking metformin
- BMI in the range 22-45
- Blood glucose criteria must be met
Exclusion
- Pregnancy or lactation
- Type 1 diabetes or diabetes resulting from pancreatic injury
- Cardiovascular complications as defined by the protocol
- Significant diabetic complications as defined by the protocol
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00351585
Start Date
July 1 2004
End Date
September 1 2005
Last Update
May 7 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.